Ausgabe 7/2011
Inhalt (5 Artikel)
Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?
Erin Schwenger, Jane Dumontet, Mary H. H. Ensom
Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders
Venkatesh Pilla Reddy, Magdalena Kozielska, Martin Johnson, An Vermeulen, Rik de Greef, Jing Liu, Geny M. M. Groothuis, Meindert Danhof, Johannes H. Proost
Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients
François Glowacki, Arnaud Lionet, Jean-Philippe Hammelin, Myriam Labalette, François Provôt, Marc Hazzan, Franck Broly, Christian Noël, Christelle Cauffiez
Lidocaine (Lignocaine) Dosing Regimen Based upon a Population Pharmacokinetic Model for Preterm and Term Neonates with Seizures
Marcel P. H. van den Broek, Alwin D. R. Huitema, Johan G. C. van Hasselt, Floris Groenendaal, Mona C. Toet, Toine C. G. Egberts, Linda S. de Vries, Catharine M. A. Rademaker
Asenapine Pharmacokinetics in Hepatic and Renal Impairment
Pierre Peeters, Howard Bockbrader, Edwin Spaans, Peter Dogterom, Kenneth Lasseter, Thomas Marbury, Gordon L. Gibson, Rik de Greef